Pivotal role of nitric oxide in the control of blood pressure after leptin administration

Diabetes

Volumn 48, Issue 4, 1999, Pages 903-908

  Frühbeck, Gema ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; LEPTIN RECEPTOR; NITRATE; NITRIC OXIDE; NITRITE;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; HEART RATE; HORMONE ACTION; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

EID: 0037907471     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.4.903     Document Type: Article

References (34)

1. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, Sacks F, Stampfer MJ: A prospective study of nutritional factors and hypertension among U.S. men. Circulation 86:1475-1484, 1992
2. Hall JE: Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 23:381-394, 1994
3. Hsueg WA, Buchanan TA: Obesity and hypertension. Endocr Hypertens 23:405-427, 1994
4. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL: Sympathetic and cardiorenal actions of leptin. Hypertension 30:619-623, 1997
5. Dunbar JC, Hu Y, Lu H: Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 46:2040-2043, 19117
6. Shek EW, Brands MW, Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension 31:409-414, 1998
7. Casto RM, Van Ness JM, Overton JM: Effects of central leptin administration on blood pressure in nonnotensive rats. Neurosci Lett 246:29-32, 1998
8. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI: Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 100:270-278, 1997
9. Jackson EK, Li P: Human leptin has natriuretic activity in the rat. Am J Physiol 272:F333-F338, 1997
10. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Woolf EA, Monroe CA, Tepper RI: Identification and expression cloning of a leptin receptor, OB-R. Cell 83:1263-1271, 1995
11. Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeña G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR: Biological action of leptin as an angiogenic factor. Science 281:1683-1686, 1998
12. Moncada S, Palmer RMJ, Higgs EA: The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 12:365-372, 1988
13. Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101:746-752, 1990
14. Sander M, Hansen PG, Victor RG: Sympathetically mediated hypertension caused by chrome inhibition of nitric oxide. Hypertension 26:691-695, 1995
15. Stamler JS, Singel DJ, Loscalzo J: Biochemistry of nitric oxide and its redox-activated forms. Science 258:1898-1902, 1992
16. Yu WH, Walczewska A, Karanth S, McCann SM: Nitric oxide mediates leptin-induced luteinizing hormone-releasing hormone (LHRH) and LHRH and leptin-induced LH release from the pituitary gland. Endocrinology 138:5055-5058, 1997
17. Lembo G, Vecchione C, Fratta L, Marino G, De Santis D, Trimarco B: Leptin induces nitric oxide-mediated vasorelaxation in aortic rings of WKY rats (Abstract). Hypertension 32:599, 1998
18. Funahashi T. Shimomura I, Hiraoka H, Arai T, Takahashi M, Nakamura T, Nozaki S, Yamashita S, Takemura K, Tokunaga K, Matsuzawa Y: Enhanced expression of rat obese (ob) gene in adipose tissues of ventromedial hypothalamus (VMH)-lesioned rats. Biochem Biophys KPS Commun 211:4469-475, 1995
19. Frühbeck G, Aguado M, Martínez JA: In vitro lipolytic effect of leptin on mouse adipocytes: evidence for a possible autocrine-paracrine role of leptin. Biochem Biophys Res Commun 240:590-594, 1997
20. Madej T, Boguski MS, Bryant SH: Threading analysis suggests that the obese gene product may be a helical cytokine. FEBS Lett 373:13-18, 1995
21. Zhang F, Basinski MB, Beals JM, Briggs SL, Churgay LM, Clawson DK, DiMarchi RD, Furman TC, Hale JE, Hshiung HM, Schoner BE, Smith DP, Zhang XY, Wery J-P, Schevitz RW: Crystal structure of the obese protein leptin-E100. Nature 387:206-209, 1997
22. Hibbs JB Jr, Westenfelder C, Taintor R, Vavrin Z, Kablitz C, Baranowski RL, Ward JH, Menlove RL, McMurry MP, Kushner JP, Samlowski WK: Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 89:867-877, 1992
23. López-Talavera JC, Levitzki A, Martínez M, Gazit A, Esteban R, Guardia J: Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. J Clin Invest 100:604-670, 1997
24. G-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo: a role for nitric oxide in the central regulation of sympathetic tone? Circ Res 70:607-611, 1992
25. Zanzinger J, Czachurski J, Seller H: Inhibition of sympathetic vasoconstriction is a major principle of vasodilation by nitric oxide in vivo. Circ Res 75:1073-1077, 1994
26. Liu J-L, Murakami H, Zucker IH: Angiotensin II-nitric oxide interaction on sympathetic outflow in conscious rabbits. Circ Res 82:496-502, 1998
27. Han S, Yang C-L, Chen X, Naes L, Cox BF, Westfall T: Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction. Am J Physiol 274:H290-H294, 1998
28. Pedrazzini T, Seydoux J, Künstner P, Aubert J-F, Grouzmann E, Beermann F, Brunner H-R: Cardiovascular response, feeding behavior, and locomotor activity in mice lacking the NPY Y1 receptor. Nature Med 4:722-726, 1998
29. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, Kriauciunas A, MacKellar W, Rosteck PR Jr, Schoner B, Smith D, Tinsley FC, Zhang X-Y, Heiman M: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 377:530-532, 1995
30. Wu X, Makynen H, Kanonen M, Arvola P, Porsti I: Mesenteric arterial function in vitro in three models of experimental hypertension. J Hypertens 14:365-372, 1990
31. Morley JE, Mattammal MB: Nitric oxide synthase levels in obese Zucker rats. Neurosci Lett 209:137-139, 1996
32. Russell JC, Graham SE, Dolphin PJ, Amy RM, Wood GO, Brindley DN: Antiatherogenic effects of long-term benfluorox treatment in male insulin-resistant JCR:LA-cp rats. Atherosclerosis 132:187-197, 1997
33. Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon III RO, Panza JA: Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation 97:851-856, 1998
34. Lyons D, Roy S, Patel M, Benjamin N, Swift CG: Impaired nitric oxide-mediated vasodilatation and total body nitric oxide production in healthy old age. Clin Sci 93:519-523, 1997